| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AGER |
| Uniprot No | Q15109 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-344aa |
| 氨基酸序列 | AQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALA |
| 预测分子量 | 36.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AGER(晚期糖基化终产物受体)重组蛋白的参考文献示例(文献信息为模拟概括，仅供参考)：
1. **文献名称**：*Expression and functional characterization of recombinant soluble RAGE in inflammatory disease models*
**作者**：Smith A, et al.
**摘要**：研究通过哺乳动物表达系统成功表达可溶性重组RAGE蛋白(sRAGE)，验证其通过竞争性结合配体抑制炎症信号通路的活性，在糖尿病小鼠模型中显示出减轻血管损伤的作用。
2. **文献名称**：*Structural analysis of AGER extracellular domain reveals ligand-binding mechanisms*
**作者**：Chen L, et al.
**摘要**：利用重组表达的AGER胞外域蛋白进行X射线晶体学分析，揭示其与HMGB1和S100蛋白等配体的结合位点，为开发靶向RAGE的抑制剂提供结构基础。
3. **文献名称**：*Recombinant RAGE fusion protein attenuates Alzheimer’s disease pathology in vitro*
**作者**：Wang Y, et al.
**摘要**：构建RAGE-Fc重组融合蛋白，证明其通过阻断β-淀粉样蛋白与细胞表面RAGE的相互作用，减少神经元氧化应激反应和炎症因子释放，具有潜在治疗阿尔茨海默病的价值。
4. **文献名称**：*High-yield production of bioactive human RAGE in Escherichia coli*
**作者**：Kumar P, et al.
**摘要**：优化大肠杆菌表达系统，实现高产量、可溶性的重组人源RAGE蛋白制备，并通过体外实验验证其与配体结合的功能活性，为低成本规模化生产提供方案。
注：以上内容基于对相关领域研究的概括，实际文献需通过PubMed或Web of Science等数据库检索确认。
**Background of AGER Recombinant Protein**
The Advanced Glycation End-product Receptor (AGER), also known as RAGE (Receptor for Advanced Glycation End-products), is a transmembrane protein belonging to the immunoglobulin superfamily. It plays a critical role in mediating inflammatory responses and cellular dysfunction by binding to various ligands, including advanced glycation end-products (AGEs), amyloid-β peptides, S100/calgranulins, and HMGB1. These ligands are often associated with chronic diseases such as diabetes, Alzheimer’s disease, atherosclerosis, and cancer. AGER activation triggers pro-inflammatory signaling pathways, such as NF-κB and MAPK, contributing to oxidative stress, tissue damage, and disease progression.
Recombinant AGER protein is engineered using biotechnological methods, typically expressed in mammalian or bacterial host systems to ensure proper folding and post-translational modifications. It often includes the extracellular ligand-binding domain (soluble RAGE or sRAGE), which can act as a decoy receptor to neutralize circulating ligands, thereby inhibiting pathological RAGE signaling. This recombinant form is widely used in research to study RAGE-ligand interactions, screen therapeutic inhibitors, and elucidate mechanisms underlying chronic inflammatory and degenerative disorders.
The development of AGER recombinant protein has advanced drug discovery, particularly for conditions driven by RAGE hyperactivity. Studies highlight its potential in mitigating complications of diabetes, neurodegeneration, and autoimmune diseases. However, the dual role of RAGE in physiological processes (e.g., tissue repair) and pathological states necessitates careful therapeutic targeting. Overall, AGER recombinant protein serves as a vital tool for both basic research and translational applications in understanding and treating RAGE-mediated diseases.
×
